Moderna (MRNA) Financials

$26.20 +1.70 (+6.94%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$26.32 +0.12 (+0.46%)

As of 04/11/2025 07:59 PM Eastern

Annual Income Statements for Moderna

This table shows Moderna's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-230	-270	-402	-514	-747	12,202	8,362	-4,714	-3,561
Consolidated Net Income / (Loss)	-216	-256	-385	-514	-747	12,202	8,362	-4,714	-3,561
Net Income / (Loss) Continuing Operations	-216	-256	-385	-514	-747	12,202	8,362	-4,714	-3,561
Total Pre-Tax Income	-215	-256	-384	-515	-744	13,285	9,575	-3,942	-3,607
Total Operating Income	-224	-269	-413	-546	-763	13,296	9,420	-4,239	-3,945
Total Gross Profit	108	206	135	60	795	15,854	13,847	2,155	1,772
Total Revenue	108	206	135	60	803	18,471	19,263	6,848	3,236
Operating Revenue	108	206	135	60	803	18,471	19,263	6,848	3,236
Total Cost of Revenue	0.00	0.00	0.00	0.00	8.00	2,617	5,416	4,693	1,464
Operating Cost of Revenue	-	-	0.00	0.00	8.00	2,617	5,416	4,693	1,464
Total Operating Expenses	332	475	548	606	1,558	2,558	4,427	6,394	5,717
Selling, General & Admin Expense	57	65	94	110	188	567	1,132	1,549	1,174
Research & Development Expense	275	410	454	496	1,370	1,991	3,295	4,845	4,543
Total Other Income / (Expense), net	8.60	13	29	31	19	-11	155	297	338
Interest & Investment Income	11	15	27	39	25	18	200	421	425
Other Income / (Expense), net	-2.71	-1.88	1.84	-8.00	-6.00	-29	-45	-124	-87
Income Tax Expense	1.04	-0.08	0.33	-1.00	3.00	1,083	1,213	772	-46
Basic Earnings per Share	($3.79)	($4.18)	($4.95)	($1.55)	($1.96)	$30.31	$21.26	($12.33)	($9.28)
Weighted Average Basic Shares Outstanding	60.75M	64.50M	81.11M	331M	381M	403M	394M	382M	384M
Diluted Earnings per Share	($3.79)	($4.18)	($4.95)	($1.55)	($1.96)	$28.29	$20.12	($12.33)	($9.28)
Weighted Average Diluted Shares Outstanding	60.75M	64.50M	81.11M	331M	381M	431M	416M	382M	384M
Weighted Average Basic & Diluted Shares Outstanding	60.75M	64.50M	81.11M	330.80M	381.33M	402.87M	386.34M	382.07M	385.82M

This table shows Moderna's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	1,043	1,465	79	-1,380	-3,630	217	-1,175	-1,279	13	-1,120
Consolidated Net Income / (Loss)	1,043	1,465	79	-1,380	-3,630	217	-1,175	-1,279	13	-1,120
Net Income / (Loss) Continuing Operations	1,043	1,465	79	-1,380	-3,630	217	-1,175	-1,279	13	-1,120
Total Pre-Tax Income	1,217	1,655	-305	-1,749	-1,958	70	-1,165	-1,279	21	-1,184
Total Operating Income	1,166	1,580	-366	-1,867	-2,012	6.00	-1,266	-1,363	-70	-1,246
Total Gross Profit	2,264	3,166	1,070	-387	-410	1,882	71	126	1,348	227
Total Revenue	3,364	5,084	1,862	344	1,831	2,811	167	241	1,862	966
Operating Revenue	3,364	5,084	1,862	344	1,831	2,811	167	241	1,862	966
Total Cost of Revenue	1,100	1,918	792	731	2,241	929	96	115	514	739
Operating Cost of Revenue	1,100	1,918	792	731	2,241	929	96	115	514	739
Total Operating Expenses	1,098	1,586	1,436	1,480	1,602	1,876	1,337	1,489	1,418	1,473
Selling, General & Admin Expense	278	375	305	332	442	470	274	268	281	351
Research & Development Expense	820	1,211	1,131	1,148	1,160	1,406	1,063	1,221	1,137	1,122
Total Other Income / (Expense), net	51	75	61	118	54	64	101	84	91	62
Interest & Investment Income	58	87	109	104	105	103	120	111	103	91
Other Income / (Expense), net	-7.00	-12	-48	14	-51	-39	-19	-27	-12	-29
Income Tax Expense	174	190	-384	-369	1,672	-147	10	0.00	8.00	-64
Basic Earnings per Share	$2.67	$3.95	$0.20	($3.62)	($9.53)	$0.62	($3.07)	($3.33)	$0.03	($2.91)
Weighted Average Basic Shares Outstanding	390M	394M	386M	381M	381M	382M	382M	384M	385M	384M
Diluted Earnings per Share	$2.53	$3.77	$0.19	($3.62)	($9.53)	$0.63	($3.07)	($3.33)	$0.03	($2.91)
Weighted Average Diluted Shares Outstanding	412M	416M	405M	381M	381M	382M	382M	384M	399M	384M
Weighted Average Basic & Diluted Shares Outstanding	384.18M	386.34M	381.21M	380.59M	381.28M	382.07M	383.24M	384.40M	384.82M	385.82M

This table details how cash moves in and out of Moderna's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-109	86	523	-422	2,388	4,224	-3,643	-289	-999
Net Cash From Operating Activities	67	-331	-331	-459	2,027	13,620	4,981	-3,118	-3,004
Net Cash From Continuing Operating Activities	67	-331	-331	-459	2,027	13,620	4,981	-3,118	-3,004
Net Income / (Loss) Continuing Operations	-216	-256	-385	-514	-747	12,202	8,362	-4,714	-3,561
Consolidated Net Income / (Loss)	-216	-256	-385	-514	-747	12,202	8,362	-4,714	-3,561
Depreciation Expense	15	21	25	31	31	232	348	621	189
Amortization Expense	2.48	1.09	-1.87	-4.00	10	54	31	-61	-95
Non-Cash Adjustments To Reconcile Net Income	39	40	73	88	156	101	261	293	516
Changes in Operating Assets and Liabilities, net	226	-137	-43	-60	2,577	1,031	-4,021	743	-53
Net Cash From Investing Activities	-649	417	-373	-15	-1,672	-8,523	-5,176	4,206	1,949
Net Cash From Continuing Investing Activities	-649	417	-373	-15	-1,672	-8,523	-5,176	4,206	1,949
Purchase of Property, Plant & Equipment	-33	-58	-106	-32	-68	-284	-400	-707	-1,051
Acquisitions	-	-	-	-	-	0.00	0.00	-85	0.00
Purchase of Investments	-1,415	-727	-1,228	-1,145	-2,956	-12,652	-11,435	-3,760	-6,529
Sale and/or Maturity of Investments	809	1,203	960	1,162	1,352	4,443	6,699	8,781	9,529
Other Investing Activities, net	-8.90	-	-	0.00	0.00	-30	-40	-23	0.00
Net Cash From Financing Activities	473	0.17	1,227	52	2,033	-873	-3,448	-1,377	56
Net Cash From Continuing Financing Activities	474	0.17	1,227	52	2,033	-873	-3,448	-1,377	56
Repurchase of Common Equity	-	-	-	0.00	0.00	-857	-3,329	-1,153	0.00
Issuance of Common Equity	0.01	0.21	564	51	2,039	124	65	46	66
Other Financing Activities, net	0.00	1.44	9.46	1.00	-6.00	-140	-184	-270	-10
Cash Interest Paid	0.00	0.00	3.00	6.00	9.00	14	25	39	24
Cash Income Taxes Paid	0.91	0.40	0.29	0.00	1.00	480	2,729	-357	197

This table details how cash moves in and out of Moderna's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	156	176	244	361	-869	-25	-857	409	-833	282
Net Cash From Operating Activities	252	1,662	-1,225	-915	-1,600	622	-989	-1,274	-1,566	825
Net Cash From Continuing Operating Activities	252	1,662	-1,225	-915	-1,600	622	-989	-1,274	-1,566	825
Net Income / (Loss) Continuing Operations	1,043	1,465	79	-1,380	-3,630	217	-1,175	-1,279	13	-1,120
Consolidated Net Income / (Loss)	1,043	1,465	79	-1,380	-3,630	217	-1,175	-1,279	13	-1,120
Depreciation Expense	113	80	78	92	249	202	36	41	52	60
Amortization Expense	6.00	-4.00	-17	-12	-12	-20	-27	-28	-21	-19
Non-Cash Adjustments To Reconcile Net Income	92	59	97	26	92	78	127	91	126	172
Changes in Operating Assets and Liabilities, net	-1,002	62	-1,462	359	1,701	145	50	-99	-1,736	1,732
Net Cash From Investing Activities	945	-1,048	2,011	1,944	789	-538	118	1,649	721	-539
Net Cash From Continuing Investing Activities	945	-1,048	2,011	1,944	789	-538	118	1,649	721	-539
Purchase of Property, Plant & Equipment	-89	-92	-113	-234	-140	-220	-196	-182	-151	-522
Purchase of Investments	-191	-2,510	-1,085	-196	-816	-1,663	-2,544	-846	-1,251	-1,888
Sale and/or Maturity of Investments	1,225	1,559	3,317	2,374	1,745	1,345	2,858	2,677	2,123	1,871
Net Cash From Financing Activities	-1,041	-438	-542	-668	-58	-109	14	34	11	-3.00
Net Cash From Continuing Financing Activities	-1,041	-438	-542	-668	-58	-109	14	34	11	-3.00
Issuance of Common Equity	11	25	9.00	16	6.00	15	15	32	8.00	11
Other Financing Activities, net	-46	-61	-25	-56	-65	-124	-1.00	2.00	3.00	-14

This table presents Moderna's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,084	2,020	1,589	7,337	24,669	25,858	18,426	14,142
Total Current Assets	783	37	1,129	6,298	16,071	13,431	10,325	8,099
Cash & Equivalents	135	-	236	2,624	6,848	3,205	2,907	1,927
Short-Term Investments	621	-	867	1,984	3,879	6,697	5,697	5,098
Accounts Receivable	13	8.95	5.37	1,391	3,175	1,385	892	358
Inventories, net	-	-	0.00	47	1,441	949	202	117
Prepaid Expenses	13	28	19	252	728	1,195	627	599
Plant, Property, & Equipment, net	139	209	0.00	0.00	1,241	2,018	1,945	2,196
Total Noncurrent Assets	162	63	461	1,039	7,357	10,409	6,156	3,847
Long-Term Investments	146	-	160	639	6,843	8,318	4,677	2,494
Other Noncurrent Operating Assets	16	63	301	400	188	1,109	1,479	1,353
Total Liabilities & Shareholders' Equity	1,084	2,020	1,589	7,337	24,669	25,858	18,426	14,142
Total Liabilities	459	355	415	4,776	10,524	6,735	4,572	3,241
Total Current Liabilities	191	91	143	4,389	9,128	4,923	3,015	2,206
Accounts Payable	21	-	7.09	18	302	487	520	405
Accrued Expenses	73	-	68	470	1,472	2,101	1,798	1,427
Current Deferred Revenue	97	82	63	3,867	6,253	2,038	568	153
Other Current Liabilities	1.28	9.33	5.06	34	225	249	129	221
Total Noncurrent Liabilities	268	264	271	387	1,396	1,812	1,557	1,035
Noncurrent Deferred Revenue	251	162	139	177	615	673	83	58
Other Noncurrent Operating Liabilities	1.53	64	94	100	781	1,139	1,474	977
Commitments & Contingencies	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-551	-982	1,175	2,561	14,145	19,123	13,854	10,901
Total Preferred & Common Equity	-551	-982	1,175	2,561	14,145	19,123	13,854	10,901
Preferred Stock	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-551	-982	1,175	2,561	14,145	19,123	13,854	10,901
Common Stock	72	-	2,669	4,802	4,211	1,173	371	866
Retained Earnings	-622	-982	-1,496	-2,244	9,958	18,320	13,606	10,045
Accumulated Other Comprehensive Income / (Loss)	-1.16	-	1.80	3.00	-24	-370	-123	-10

This table presents Moderna's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	26,056	25,858	24,125	21,884	19,450	18,426	16,729	15,680	15,803	14,142
Total Current Assets	14,297	13,431	12,122	10,599	10,799	10,325	9,600	9,661	9,666	8,099
Cash & Equivalents	3,027	3,205	3,441	3,801	2,932	2,907	2,051	2,478	1,644	1,927
Short-Term Investments	5,321	6,697	5,482	4,658	4,641	5,697	6,472	6,010	5,223	5,098
Accounts Receivable	2,695	1,385	1,113	232	1,866	892	137	163	1,564	358
Inventories, net	2,077	949	732	715	487	202	295	399	412	117
Prepaid Expenses	1,177	1,195	1,354	1,193	873	627	645	611	823	599
Plant, Property, & Equipment, net	2,019	2,018	2,018	2,280	1,952	1,945	2,063	2,196	2,381	2,196
Total Noncurrent Assets	9,740	10,409	9,985	9,005	6,699	6,156	5,066	3,823	3,756	3,847
Long-Term Investments	8,655	8,318	7,442	6,105	5,273	4,677	3,638	2,326	2,335	2,494
Other Noncurrent Operating Assets	165	1,109	1,281	1,420	1,426	1,479	1,347	1,416	1,340	1,353
Total Liabilities & Shareholders' Equity	26,056	25,858	24,125	21,884	19,450	18,426	16,729	15,680	15,803	14,142
Total Liabilities	8,064	6,735	5,262	4,935	5,995	4,572	3,912	3,968	3,876	3,241
Total Current Liabilities	6,807	4,923	3,499	3,123	4,385	3,015	2,380	2,363	2,201	2,206
Accounts Payable	330	487	389	310	494	520	183	279	373	405
Accrued Expenses	1,856	2,101	1,613	1,490	2,224	1,798	1,396	1,333	1,376	1,427
Current Deferred Revenue	4,002	2,038	1,219	1,040	1,372	568	559	702	379	153
Other Current Liabilities	553	249	212	236	239	129	190	42	69	221
Total Noncurrent Liabilities	1,257	1,812	1,763	1,812	1,610	1,557	1,532	1,605	1,675	1,035
Noncurrent Deferred Revenue	175	673	673	692	166	83	58	95	95	58
Other Noncurrent Operating Liabilities	1,082	1,139	1,090	1,120	869	1,474	899	1,510	955	977
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	17,992	19,123	18,863	16,949	13,455	13,854	12,817	11,712	11,927	10,901
Total Preferred & Common Equity	17,992	19,123	18,863	16,949	13,455	13,854	12,817	11,712	11,927	10,901
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	17,992	19,123	18,863	16,949	13,455	13,854	12,817	11,712	11,927	10,901
Common Stock	1,488	1,173	731	193	277	371	487	631	751	866
Retained Earnings	16,855	18,320	18,399	17,019	13,389	13,606	12,431	11,152	11,165	10,045
Accumulated Other Comprehensive Income / (Loss)	-351	-370	-267	-263	-211	-123	-101	-71	11	-10

This table displays calculated financial ratios and metrics derived from Moderna's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	89.88%	-34.38%	-55.58%	1,238.33%	2,200.25%	4.29%	-64.45%	-52.75%
EBITDA Growth	0.00%	-19.49%	-55.62%	-35.67%	-38.14%	1,961.68%	-28.03%	-138.99%	-3.55%
EBIT Growth	0.00%	-19.76%	-51.69%	-34.65%	-38.81%	1,825.23%	-29.34%	-146.54%	7.59%
NOPAT Growth	0.00%	-20.37%	-53.43%	-32.12%	-39.74%	2,386.48%	-32.64%	-136.07%	6.94%
Net Income Growth	0.00%	-18.36%	-50.34%	-33.60%	-45.33%	1,733.47%	-31.47%	-156.37%	24.46%
EPS Growth	0.00%	-10.29%	-18.42%	68.69%	-26.45%	1,543.37%	-28.88%	-161.28%	24.74%
Operating Cash Flow Growth	0.00%	-596.72%	0.19%	-38.73%	541.61%	571.93%	-63.43%	-162.60%	3.66%
Free Cash Flow Firm Growth	0.00%	0.00%	-841.82%	37.64%	687.30%	555.88%	-70.15%	-167.65%	-35.38%
Invested Capital Growth	0.00%	0.00%	97.18%	-583.44%	-4,998.97%	-32.96%	126.37%	-36.54%	141.19%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-26.45%	226.63%	56.12%	-9.94%	-24.92%	-36.31%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	3.61%	-23.64%	74.02%	-28.34%	-64.77%	-54.13%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	3.14%	-22.80%	74.82%	-29.03%	-57.97%	-44.52%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	4.07%	-23.49%	72.79%	-29.65%	-59.06%	-46.49%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	3.41%	-25.07%	72.81%	-28.92%	-36.01%	-60.12%
EPS Q/Q Growth	0.00%	0.00%	0.00%	30.18%	-20.99%	73.66%	-27.21%	-34.17%	-61.67%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-1.78%	205.30%	17.68%	-24.86%	-50.05%	6.33%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	175.37%	17.86%	-28.88%	-27.99%	11.86%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	6.14%	-112.98%	34.44%	-8.70%	-51.60%	-58.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	99.00%	85.83%	71.88%	31.47%	54.76%
EBITDA Margin	-192.71%	-121.27%	-287.58%	-878.33%	-90.66%	73.37%	50.64%	-55.53%	-121.69%
Operating Margin	-206.44%	-130.87%	-305.97%	-910.00%	-95.02%	71.98%	48.90%	-61.90%	-121.91%
EBIT Margin	-208.94%	-131.78%	-304.61%	-923.33%	-95.77%	71.83%	48.67%	-63.71%	-124.60%
Profit (Net Income) Margin	-199.46%	-124.34%	-284.84%	-856.67%	-93.03%	66.06%	43.41%	-68.84%	-110.04%
Tax Burden Percent	100.48%	99.97%	100.08%	99.81%	100.40%	91.85%	87.33%	119.58%	98.72%
Interest Burden Percent	95.01%	94.38%	93.43%	92.96%	96.75%	100.14%	102.13%	90.35%	89.46%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	8.15%	12.67%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-402.07%	-282.51%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-390.98%	-275.49%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	373.48%	253.74%
Return on Equity (ROE)	0.00%	-40.93%	215.46%	-534.36%	-39.99%	146.08%	50.27%	-28.59%	-28.77%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	431.74%	-357.36%	-365.27%
Operating Return on Assets (OROA)	0.00%	-25.01%	-26.51%	-30.70%	-17.23%	82.90%	37.11%	-19.70%	-24.76%
Return on Assets (ROA)	0.00%	-23.60%	-24.79%	-28.48%	-16.74%	76.25%	33.10%	-21.29%	-21.87%
Return on Common Equity (ROCE)	0.00%	36.09%	925.32%	-534.36%	-39.99%	146.08%	50.27%	-28.59%	-28.77%
Return on Equity Simple (ROE_SIMPLE)	0.00%	46.42%	39.16%	-43.75%	-29.17%	86.26%	43.73%	-34.03%	-32.67%
Net Operating Profit after Tax (NOPAT)	-157	-189	-289	-382	-534	12,212	8,227	-2,967	-2,762
NOPAT Margin	-144.51%	-91.61%	-214.18%	-637.00%	-66.51%	66.12%	42.71%	-43.33%	-85.34%
Net Nonoperating Expense Percent (NNEP)	0.00%	-15.19%	217.18%	-105.32%	-6.69%	-0.09%	0.76%	-11.09%	-7.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	43.02%	-21.42%	-25.33%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	1.00%	14.17%	28.12%	68.53%	45.24%
SG&A Expenses to Revenue	53.00%	31.45%	69.78%	183.33%	23.41%	3.07%	5.88%	22.62%	36.28%
R&D to Revenue	253.44%	199.42%	336.19%	826.67%	170.61%	10.78%	17.11%	70.75%	140.39%
Operating Expenses to Revenue	306.44%	230.87%	405.97%	1,010.00%	194.02%	13.85%	22.98%	93.37%	176.67%
Earnings before Interest and Taxes (EBIT)	-226	-271	-411	-554	-769	13,267	9,375	-4,363	-4,032
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-209	-250	-388	-527	-728	13,553	9,754	-3,803	-3,938
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	5.55	16.14	7.28	3.61	2.74	1.47
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	5.55	16.14	7.28	3.61	2.74	1.47
Price to Revenue (P/Rev)	5.58	2.94	2.97	108.64	51.48	5.58	3.58	5.54	4.94
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	8.44	8.25	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	11.85%	12.12%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	56.24	43.00	4.69
Enterprise Value to Revenue (EV/Rev)	0.00	4.34	3.25	88.22	45.08	4.62	2.64	3.60	2.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	6.30	5.21	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	6.44	5.42	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	6.99	6.17	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	17.86	6.27	10.20	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	12.19	0.00	0.00	18.18	6.54	13.03	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	-0.04	0.03	0.04	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.03	-0.04	0.03	0.04	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.42	-0.25	-1.30	-1.70	-1.36	-1.08	-0.96	-0.92
Leverage Ratio	0.00	1.73	-8.69	18.76	2.39	1.92	1.52	1.34	1.32
Compound Leverage Factor	0.00	1.64	-8.12	17.44	2.31	1.92	1.55	1.21	1.18
Debt to Total Capital	0.00%	2.45%	-3.99%	3.19%	4.12%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	2.45%	-3.99%	3.19%	4.12%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	183.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-86.02%	103.99%	96.81%	95.88%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.06	-0.10	-0.07	-0.15	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	3.55	-0.10	2.33	7.06	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.06	-0.10	-0.07	-0.15	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.08	-0.13	-0.10	-0.21	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.71	-0.13	3.21	9.62	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.08	-0.13	-0.10	-0.21	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.01	-0.64	7.75	4.84	9.30	9.48	6.08	3.74
Noncontrolling Interest Sharing Ratio	0.00%	188.18%	-329.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	4.09	0.41	7.89	1.44	1.76	2.73	3.42	3.67
Quick Ratio	0.00	4.02	0.10	7.74	1.37	1.52	2.29	3.15	3.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	73	-544	-339	1,991	13,061	3,899	-2,637	-3,571
Operating Cash Flow to CapEx	201.35%	-567.60%	-312.83%	-1,434.38%	2,980.88%	4,795.77%	1,245.25%	-441.02%	-285.82%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.19	0.09	0.03	0.18	1.15	0.76	0.31	0.20
Accounts Receivable Turnover	0.00	15.34	12.08	8.38	1.15	8.09	8.45	6.01	5.18
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	3.52	4.53	8.15	9.18
Fixed Asset Turnover	0.00	1.48	0.78	0.00	0.00	0.00	11.82	3.46	1.56
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.64	16.36	13.73	9.32	3.17
Days Sales Outstanding (DSO)	0.00	23.79	30.22	43.55	317.36	45.11	43.20	60.68	70.50
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	103.77	80.53	44.76	39.77
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	572.37	22.32	26.59	39.16	115.31
Cash Conversion Cycle (CCC)	0.00	23.79	30.22	43.55	-255.01	126.57	97.15	66.28	-5.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-262	-7.39	-51	-2,576	-3,425	903	573	1,382
Invested Capital Turnover	0.00	-1.57	-1.00	-2.07	-0.61	-6.16	-15.28	9.28	3.31
Increase / (Decrease) in Invested Capital	0.00	-262	254	-43	-2,525	-849	4,328	-330	809
Enterprise Value (EV)	0.00	894	439	5,293	36,203	85,406	50,786	24,638	6,482
Market Capitalization	604	604	401	6,518	41,340	102,976	69,006	37,919	16,001
Book Value per Share	$0.00	($8.55)	($12.11)	$3.53	$6.47	$34.89	$49.78	$36.34	$28.33
Tangible Book Value per Share	$0.00	($8.55)	($12.11)	$3.53	$6.47	$34.89	$49.78	$36.34	$28.33
Total Capital	0.00	641	-945	1,213	2,671	14,145	19,123	13,854	10,901
Total Debt	0.00	16	38	39	110	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	16	38	39	110	0.00	0.00	0.00	0.00
Net Debt	0.00	-887	38	-1,225	-5,137	-17,570	-18,220	-13,281	-9,519
Capital Expenditures (CapEx)	33	58	106	32	68	284	400	707	1,051
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-165	-54	-118	-2,699	-3,784	-1,394	-1,294	-1,132
Debt-free Net Working Capital (DFNWC)	0.00	592	-54	986	1,909	6,943	8,508	7,310	5,893
Net Working Capital (NWC)	0.00	592	-54	986	1,909	6,943	8,508	7,310	5,893
Net Nonoperating Expense (NNE)	60	67	95	132	213	10	-135	1,747	800
Net Nonoperating Obligations (NNO)	0.00	-887	975	-1,225	-5,137	-17,570	-18,220	-13,281	-9,519
Total Depreciation and Amortization (D&A)	18	22	23	27	41	286	379	560	94
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-80.27%	-40.02%	-197.24%	-336.11%	-20.49%	-7.24%	-18.90%	-34.98%
Debt-free Net Working Capital to Revenue	0.00%	287.51%	-40.02%	1,642.82%	237.73%	37.59%	44.17%	106.75%	182.11%
Net Working Capital to Revenue	0.00%	287.51%	-40.02%	1,642.82%	237.73%	37.59%	44.17%	106.75%	182.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.79)	($4.18)	($4.95)	($1.55)	($1.96)	$30.31	$21.26	($12.33)	($9.28)
Adjusted Weighted Average Basic Shares Outstanding	60.75M	64.50M	329.00M	368.64M	399.77M	403M	394M	382M	384M
Adjusted Diluted Earnings per Share	($3.79)	($4.18)	($4.95)	($1.55)	($1.96)	$28.29	$20.12	($12.33)	($9.28)
Adjusted Weighted Average Diluted Shares Outstanding	60.75M	64.50M	329.00M	368.64M	399.77M	431M	416M	382M	384M
Adjusted Basic & Diluted Earnings per Share	($3.79)	($4.18)	($4.95)	($1.55)	($1.96)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	60.75M	64.50M	81.11M	330.80M	381.33M	402.87M	386.34M	382.07M	385.82M
Normalized Net Operating Profit after Tax (NOPAT)	-157	-189	-289	-382	-534	12,212	8,227	-2,967	-2,762
Normalized NOPAT Margin	-144.51%	-91.61%	-214.18%	-637.00%	-66.51%	66.12%	42.71%	-43.33%	-85.34%
Pre Tax Income Margin	-198.50%	-124.38%	-284.60%	-858.33%	-92.65%	71.92%	49.71%	-57.56%	-111.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	7.02%	39.81%	-24.46%	0.00%

This table displays calculated financial ratios and metrics derived from Moderna's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-32.30%	-29.50%	-69.30%	-92.76%	-45.57%	-44.71%	-91.03%	-29.94%	1.69%	-65.64%
EBITDA Growth	-64.87%	-70.12%	-108.19%	-170.33%	-242.88%	-90.94%	-261.47%	22.34%	97.21%	-928.19%
EBIT Growth	-67.33%	-70.98%	-109.82%	-176.13%	-278.00%	-102.10%	-210.39%	24.99%	96.03%	-3,763.64%
NOPAT Growth	-70.07%	-71.27%	-107.01%	-160.14%	-240.94%	-98.67%	-245.90%	27.00%	96.92%	-4,789.25%
Net Income Growth	-68.71%	-69.91%	-97.84%	-162.81%	-448.03%	-85.19%	-1,587.34%	7.32%	100.36%	-616.13%
EPS Growth	-67.14%	-66.61%	-97.79%	-169.08%	-476.68%	-83.29%	-1,715.79%	8.01%	100.31%	-561.90%
Operating Cash Flow Growth	-92.31%	-49.79%	-144.34%	-400.99%	-734.92%	-62.58%	19.27%	-39.24%	2.13%	32.64%
Free Cash Flow Firm Growth	-170.90%	-151.24%	-605.01%	19.61%	69.25%	111.90%	108.82%	117.05%	-37.79%	-582.27%
Invested Capital Growth	118.93%	126.37%	259.62%	320.63%	19.72%	-36.54%	-50.72%	-62.35%	182.94%	141.19%
Revenue Q/Q Growth	-29.16%	51.13%	-63.38%	-81.53%	432.27%	53.52%	-94.06%	44.31%	672.61%	-48.12%
EBITDA Q/Q Growth	-49.31%	28.64%	-121.47%	-402.27%	-2.99%	108.16%	-956.38%	-7.92%	96.30%	-2,319.61%
EBIT Q/Q Growth	-52.38%	35.29%	-126.40%	-347.58%	-11.33%	98.40%	-3,793.94%	-8.17%	94.10%	-1,454.88%
NOPAT Q/Q Growth	-54.01%	39.96%	-118.32%	-410.11%	-7.77%	101.32%	-4,864.52%	-7.66%	95.46%	-1,912.77%
Net Income Q/Q Growth	-52.53%	40.46%	-94.61%	-1,846.84%	-163.04%	105.98%	-641.47%	-8.85%	101.02%	-8,715.38%
EPS Q/Q Growth	-51.72%	49.01%	-94.96%	-2,005.26%	-163.26%	106.61%	-587.30%	-8.47%	100.90%	-9,800.00%
Operating Cash Flow Q/Q Growth	-17.11%	559.52%	-173.71%	25.31%	-74.86%	138.88%	-259.00%	-28.82%	-22.92%	152.68%
Free Cash Flow Firm Q/Q Growth	-34.13%	43.81%	-47.44%	27.65%	48.69%	121.74%	9.24%	39.94%	-514.59%	23.90%
Invested Capital Q/Q Growth	74.43%	-8.70%	176.63%	-4.52%	-50.36%	-51.60%	114.83%	-27.05%	273.05%	-58.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.30%	62.27%	57.47%	-112.50%	-22.39%	66.95%	42.52%	52.28%	72.40%	23.50%
EBITDA Margin	37.99%	32.34%	-18.96%	-515.41%	-99.73%	5.30%	-764.07%	-571.37%	-2.74%	-127.74%
Operating Margin	34.66%	31.08%	-19.66%	-542.73%	-109.89%	0.21%	-758.08%	-565.56%	-3.76%	-128.99%
EBIT Margin	34.45%	30.84%	-22.23%	-538.66%	-112.67%	-1.17%	-769.46%	-576.76%	-4.40%	-131.99%
Profit (Net Income) Margin	31.00%	28.82%	4.24%	-401.16%	-198.25%	7.72%	-703.59%	-530.71%	0.70%	-115.94%
Tax Burden Percent	85.70%	88.52%	-25.90%	78.90%	185.39%	310.00%	100.86%	100.00%	61.90%	94.59%
Interest Burden Percent	105.00%	105.55%	73.67%	94.39%	94.91%	-212.12%	90.66%	92.01%	-25.61%	92.86%
Effective Tax Rate	14.30%	11.48%	0.00%	0.00%	0.00%	-210.00%	0.00%	0.00%	38.10%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-444.16%	-2,742.27%	-645.73%	6.14%	-1,466.60%	-1,217.94%	-5.22%	-298.90%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-446.08%	-2,741.81%	-630.55%	4.88%	-1,464.54%	-1,215.38%	-5.76%	-296.73%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	434.50%	2,510.12%	586.98%	-4.66%	1,292.15%	1,076.17%	4.73%	273.30%
Return on Equity (ROE)	83.69%	50.27%	-9.67%	-232.15%	-58.75%	1.48%	-174.45%	-141.78%	-0.49%	-25.61%
Cash Return on Invested Capital (CROIC)	554.24%	431.74%	20.73%	-71.89%	-189.65%	-357.36%	-124.98%	-107.07%	-178.70%	-365.27%
Operating Return on Assets (OROA)	31.37%	23.52%	-12.94%	-239.49%	-45.17%	-0.36%	-194.11%	-155.08%	-1.27%	-26.23%
Return on Assets (ROA)	28.23%	21.97%	2.47%	-178.35%	-79.47%	2.39%	-177.49%	-142.69%	0.20%	-23.04%
Return on Common Equity (ROCE)	83.69%	50.27%	-9.67%	-232.15%	-58.75%	1.48%	-174.45%	-141.78%	-0.49%	-25.61%
Return on Equity Simple (ROE_SIMPLE)	65.39%	0.00%	25.36%	7.12%	-25.76%	0.00%	-46.56%	-50.09%	-18.65%	0.00%
Net Operating Profit after Tax (NOPAT)	999	1,399	-256	-1,307	-1,408	19	-886	-954	-43	-872
NOPAT Margin	29.71%	27.51%	-13.76%	-379.91%	-76.92%	0.66%	-530.66%	-395.89%	-2.33%	-90.29%
Net Nonoperating Expense Percent (NNEP)	0.27%	0.37%	1.92%	-0.46%	-15.18%	1.26%	-2.07%	-2.56%	0.54%	-2.17%
Return On Investment Capital (ROIC_SIMPLE)	-	7.31%	-	-	-	0.13%	-	-	-	-8.00%
Cost of Revenue to Revenue	32.70%	37.73%	42.53%	212.50%	122.39%	33.05%	57.49%	47.72%	27.60%	76.50%
SG&A Expenses to Revenue	8.26%	7.38%	16.38%	96.51%	24.14%	16.72%	164.07%	111.20%	15.09%	36.34%
R&D to Revenue	24.38%	23.82%	60.74%	333.72%	63.35%	50.02%	636.53%	506.64%	61.06%	116.15%
Operating Expenses to Revenue	32.64%	31.20%	77.12%	430.23%	87.49%	66.74%	800.60%	617.84%	76.15%	152.48%
Earnings before Interest and Taxes (EBIT)	1,159	1,568	-414	-1,853	-2,063	-33	-1,285	-1,390	-82	-1,275
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,278	1,644	-353	-1,773	-1,826	149	-1,276	-1,377	-51	-1,234
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.57	3.61	3.15	2.73	2.92	2.74	3.17	3.89	2.15	1.47
Price to Tangible Book Value (P/TBV)	2.57	3.61	3.15	2.73	2.92	2.74	3.17	3.89	2.15	1.47
Price to Revenue (P/Rev)	2.16	3.58	3.94	4.35	4.31	5.54	7.88	9.01	5.06	4.94
Price to Earnings (P/E)	3.93	8.25	12.40	38.37	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	25.43%	12.12%	8.06%	2.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.58	56.24	17.20	13.31	22.84	43.00	23.59	38.64	5.11	4.69
Enterprise Value to Revenue (EV/Rev)	1.37	2.64	2.85	2.98	2.96	3.60	5.64	6.87	3.37	2.00
Enterprise Value to EBITDA (EV/EBITDA)	2.15	5.21	8.44	39.89	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	2.21	5.42	9.05	69.03	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	2.50	6.17	9.38	41.95	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	4.41	10.20	43.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.34	13.03	82.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.04	0.00	0.04	0.00	0.05	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.04	0.00	0.04	0.00	0.05	0.00
Financial Leverage	-1.15	-1.08	-0.97	-0.92	-0.93	-0.96	-0.88	-0.89	-0.82	-0.92
Leverage Ratio	1.67	1.52	1.44	1.37	1.45	1.34	1.29	1.31	1.39	1.32
Compound Leverage Factor	1.75	1.60	1.06	1.29	1.37	-2.85	1.17	1.21	-0.36	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	4.10%	0.00%	4.29%	0.00%	4.98%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	4.10%	0.00%	4.29%	0.00%	4.98%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	95.90%	100.00%	95.71%	100.00%	95.02%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.25	0.00	-0.12	0.00	-0.24	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	5.32	0.00	2.45	0.00	3.36	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.25	0.00	-0.12	0.00	-0.24	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.31	0.00	-0.16	0.00	-0.33	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	6.58	0.00	3.22	0.00	4.55	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.31	0.00	-0.16	0.00	-0.33	0.00
Altman Z-Score	5.66	8.48	8.83	7.34	5.41	6.85	7.84	8.47	5.84	4.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.10	2.73	3.46	3.39	2.46	3.42	4.03	4.09	4.39	3.67
Quick Ratio	1.62	2.29	2.87	2.78	2.15	3.15	3.64	3.66	3.83	3.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-5,214	-2,929	-4,319	-3,125	-1,603	349	381	533	-2,209	-1,681
Operating Cash Flow to CapEx	283.15%	1,806.52%	-1,084.07%	-391.03%	-1,142.86%	282.73%	-504.59%	-700.00%	-1,037.09%	158.05%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.91	0.76	0.58	0.44	0.40	0.31	0.25	0.27	0.29	0.20
Accounts Receivable Turnover	7.33	8.45	7.03	7.29	4.00	6.01	8.24	25.57	2.96	5.18
Inventory Turnover	2.93	4.53	3.88	3.45	4.43	8.15	7.78	6.07	3.68	9.18
Fixed Asset Turnover	0.00	11.82	8.97	0.00	4.59	3.46	2.53	2.26	2.35	1.56
Accounts Payable Turnover	21.34	13.73	17.66	18.50	13.79	9.32	13.98	11.48	3.82	3.17
Days Sales Outstanding (DSO)	49.80	43.20	51.94	50.07	91.26	60.68	44.27	14.27	123.20	70.50
Days Inventory Outstanding (DIO)	124.76	80.53	94.01	105.94	82.35	44.76	46.89	60.13	99.19	39.77
Days Payable Outstanding (DPO)	17.10	26.59	20.67	19.73	26.47	39.16	26.12	31.79	95.66	115.31
Cash Conversion Cycle (CCC)	157.46	97.15	125.28	136.28	147.15	66.28	65.05	42.61	126.73	-5.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	989	903	2,498	2,385	1,184	573	1,231	898	3,350	1,382
Invested Capital Turnover	-10.10	-15.28	32.28	7.22	8.39	9.28	2.76	3.08	2.24	3.31
Increase / (Decrease) in Invested Capital	6,213	4,328	4,063	1,818	195	-330	-1,267	-1,487	2,166	809
Enterprise Value (EV)	29,256	50,786	42,969	31,753	27,040	24,638	29,044	34,696	17,112	6,482
Market Capitalization	46,259	69,006	59,334	46,317	39,311	37,919	40,630	45,510	25,689	16,001
Book Value per Share	$45.99	$49.78	$48.82	$44.46	$35.35	$36.34	$33.55	$30.56	$31.03	$28.33
Tangible Book Value per Share	$45.99	$49.78	$48.82	$44.46	$35.35	$36.34	$33.55	$30.56	$31.03	$28.33
Total Capital	17,992	19,123	18,863	16,949	14,030	13,854	13,392	11,712	12,552	10,901
Total Debt	0.00	0.00	0.00	0.00	575	0.00	575	0.00	625	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	575	0.00	575	0.00	625	0.00
Net Debt	-17,003	-18,220	-16,365	-14,564	-12,271	-13,281	-11,586	-10,814	-8,577	-9,519
Capital Expenditures (CapEx)	89	92	113	234	140	220	196	182	151	522
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-858	-1,394	-300	-983	-1,159	-1,294	-1,303	-1,190	598	-1,132
Debt-free Net Working Capital (DFNWC)	7,490	8,508	8,623	7,476	6,414	7,310	7,220	7,298	7,465	5,893
Net Working Capital (NWC)	7,490	8,508	8,623	7,476	6,414	7,310	7,220	7,298	7,465	5,893
Net Nonoperating Expense (NNE)	-44	-66	-335	73	2,222	-198	289	325	-56	248
Net Nonoperating Obligations (NNO)	-17,003	-18,220	-16,365	-14,564	-12,271	-13,281	-11,586	-10,814	-8,577	-9,519
Total Depreciation and Amortization (D&A)	119	76	61	80	237	182	9.00	13	31	41
Debt-free, Cash-free Net Working Capital to Revenue	-4.01%	-7.24%	-1.99%	-9.23%	-12.71%	-18.90%	-25.29%	-23.56%	11.77%	-34.98%
Debt-free Net Working Capital to Revenue	35.02%	44.17%	57.26%	70.17%	70.32%	106.75%	140.11%	144.51%	146.92%	182.11%
Net Working Capital to Revenue	35.02%	44.17%	57.26%	70.17%	70.32%	106.75%	140.11%	144.51%	146.92%	182.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.67	$3.95	$0.20	($3.62)	($9.53)	$0.62	($3.07)	($3.33)	$0.03	($2.91)
Adjusted Weighted Average Basic Shares Outstanding	390M	394M	386M	381M	381M	382M	382M	384M	385M	384M
Adjusted Diluted Earnings per Share	$2.53	$3.77	$0.19	($3.62)	($9.53)	$0.63	($3.07)	($3.33)	$0.03	($2.91)
Adjusted Weighted Average Diluted Shares Outstanding	412M	416M	405M	381M	381M	382M	382M	384M	399M	384M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	384.18M	386.34M	381.21M	380.59M	381.28M	382.07M	383.24M	384.40M	384.82M	385.82M
Normalized Net Operating Profit after Tax (NOPAT)	999	1,399	-256	-1,307	-1,408	4.20	-886	-954	-43	-872
Normalized NOPAT Margin	29.71%	27.51%	-13.76%	-379.91%	-76.92%	0.15%	-530.66%	-395.89%	-2.33%	-90.29%
Pre Tax Income Margin	36.18%	32.55%	-16.38%	-508.43%	-106.94%	2.49%	-697.60%	-530.71%	1.13%	-122.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	32.16%	39.81%	67.56%	212.26%	-44.86%	-24.46%	-10.51%	0.02%	0.00%	0.00%

Frequently Asked Questions About Moderna's Financials

When does Moderna's fiscal year end?

According to the most recent income statement we have on file, Moderna's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Moderna's net income changed over the last 8 years?

Moderna's net income appears to be on an upward trend, with a most recent value of -$3.56 billion in 2024, rising from -$216.21 million in 2016. The previous period was -$4.71 billion in 2023.

What is Moderna's operating income?

Moderna's total operating income in 2024 was -$3.95 billion, based on the following breakdown:

Total Gross Profit: $1.77 billion
Total Operating Expenses: $5.72 billion

How has Moderna revenue changed over the last 8 years?

Over the last 8 years, Moderna's total revenue changed from $108.40 million in 2016 to $3.24 billion in 2024, a change of 2,885.4%.

How much debt does Moderna have?

Moderna's total liabilities were at $3.24 billion at the end of 2024, a 29.1% decrease from 2023, and a 605.8% increase since 2017.

How much cash does Moderna have?

In the past 7 years, Moderna's cash and equivalents has ranged from $0.00 in 2018 to $6.85 billion in 2021, and is currently $1.93 billion as of their latest financial filing in 2024.

How has Moderna's book value per share changed over the last 8 years?

Over the last 8 years, Moderna's book value per share changed from 0.00 in 2016 to 28.33 in 2024, a change of 2,832.8%.

Remove Ads

Related Companies

This page (NASDAQ:MRNA) was last updated on 4/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Financials

Frequently Asked Questions About Moderna's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moderna (MRNA) Financials

Annual Income Statements for Moderna

Quarterly Income Statements for Moderna

Annual Cash Flow Statements for Moderna

Quarterly Cash Flow Statements for Moderna

Annual Balance Sheets for Moderna

Quarterly Balance Sheets for Moderna

Annual Metrics and Ratios for Moderna

Quarterly Metrics and Ratios for Moderna

Frequently Asked Questions About Moderna's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools